Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

BioPorto

1.664

 

DKK

 

-0.36 %

BIOPOR

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

14 following
-0.36%
-18.43%
-18.23%
-6.41%
-20.38%
-32.08%
-45.59%
-27.75%
-30.15%
bioporto.com/Investor-Relations

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.

Read more
Revenue
30.96M
EBIT %
-197.58 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
BIOPOR
Daily low / high price
1.664 / 1.76 DKK
Market cap
714.97M DKK
Turnover
251.42K DKK
Volume
147K

Latest research

Bioporto (One-pager): From Diagnostic innovator to Diagnostic company
04.03.2024

Analyst

Claus Thestrup
Claus Thestrup
CEO, Sweden

Latest videos

BioPorto - Building the Global Commercial Platform
22.10.2024
Life Science seminar 2024
04.06.2024
BioPorto - Presentation of strategic plans
22.02.2024
Login in to make your own estimates and see other investors estimates.
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
BioPorto - Building the Global Commercial Platform
Webcast by
Claus Thestrup

BioPorto - Building the Global Commercial Platform

Mest and ask questions to Jennifer Zonderman, Senior Vice President Global Marketing & US Commercialization, and hear her present the market characteristics and BioPorto's global commercial strategy within AKI diagnostics on 22 October at 2.00 PM.

BioPorto